TOT BIOPHARM won the title of "2019 The Best Healthcare Investment Award"
On April 10, 2019, sponsored by the HaoYue capital, the theme of "breakthrough", "the 3rd Healthcare Investment Excellence List Summit" held in Intercontinental Pudong Shanghai. More than 400 well-known investment funds, enterprises, listed healthcare companies and authoritative media attended the summit. At the meeting, the list of "2019 The Best Healthhealth Investment" was officially released, and TOT BIOPHARM was awarded as "the best investment case of the year".
"The Healthcare Investment Excellence List" is a leaderboard for the medical and health field, tracking and recording the development and changes of Chinese medical and health enterprises and medical health investment institutions 2019 is the third consecutive year that this list has be release, and it has become a highly recognized annual authority list in the industry. According to the public information, the 27 companies listed in the previous two sessions have a valuation of more than 204.2 billion RMB, of which: 3 were listed on the IPO shortly after the list, and they are all leading companies in the segment.
After the registered vote of "authoritative judges, one vote for each" in this selection, TOT BIOPHARM woe the "2019 Best Healthcare Investment Case Award", which is the recognition of the development of TOT BIOPHARM in recent years. In the future, TOT BIOPHARM will adhere to the business philosophy of "balance between humanities and technology", continue to innovate and develop, and contribute to biopharmaceutical industry in China.